Hepatitis C-Induced Hepatitis Flare in a Patient with Non-Hodgkin B-Cell Lymphoma Treated by Rituximab Including Chemotherapy (Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin - Vincristine, Prednisolone) Regimen

  • Asım Ülçay GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
  • Ergenekon Karagoz GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey https://orcid.org/0000-0002-5473-3897
  • Gökhan Karaahmetoğlu GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
  • Vedat Turhan GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey https://orcid.org/0000-0001-5953-7951
  • Ali Acar GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
  • Levent Görenek GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
Keywords: Hepatitis C virus, nonhodgkin lymphoma, rituximab

Abstract

Hepatitis virus infections can lead to more critical outcomes such as severe hepatic dysfunction, failure, and fulminancy in the immunosuppressive patients other than immunocompetent individuals. It is globally accepted that reactivation of both hepatitis B virus and hepatitis C virus (HCV) occurs after chemotherapy and miscellaneous antibody treatments of malignant diseases or solid organ/bone marrow transplant in recipient patients. Especially among B-cell non-Hodgkin lymphoma (NHL) patients, according to various studies, the seroprevalance of HCV is higher than that of the general population. On the other hand, the role of HCV in the pathogenesis and etiology of NHL has been suggested. Today, cytotoxic drugs, corticosteroids, rituximab (RTX), and hepatotoxic regimens are administered to NHL patients. Specifically, it has been emphasized that the utilization of RTX (Anti CD20 antibody) regiments for B-cell NHL patients may result with flares in HCV patients conspicuously. Here, we report the case of an acute flare up due to HCV infection in a patient who underwent a 4 month course of RTX, containing chemotherapy against a B cell NHL (CD20+) disease and a
dramatic recovery from HCV infection at the end.

Author Biographies

Asım Ülçay, GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Ergenekon Karagoz, GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Gökhan Karaahmetoğlu, GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Vedat Turhan, GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Ali Acar, GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Levent Görenek, GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

GATA Haydarpaşa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey

Published
2014-09-01
How to Cite
Ülçay, A., Karagoz, E., Karaahmetoğlu, G., Turhan, V., Acar, A., & Görenek, L. (2014). Hepatitis C-Induced Hepatitis Flare in a Patient with Non-Hodgkin B-Cell Lymphoma Treated by Rituximab Including Chemotherapy (Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin - Vincristine, Prednisolone) Regimen. Disease and Molecular Medicine, 2(3), 51-54. https://doi.org/10.5455/dmm.20140921072623
Section
Case Report